Both Eli Lilly and Boehringer Ingelheim have strong Canadian operations that should facilitate regulatory submissions
Brief temperature excursions during transport from the refrigerator to injection are fine, but the vial should not sit at room temperature for extended periods
If TRIUMPH-1 lands well, expect a wave of media coverage similar to TRIUMPH-4 (front page CNBC, NYT, BBC), a vendor stock crunch in the research-peptide market within days, and a clear NDA-filing announcement from Lilly within weeks
The two forces may cancel out for many people, and tip one way or the other depending on the individual [4]
Compounded versions of semaglutide and tirzepatide represent one alternative pathway that some patients explore when brand-name coverage is unavailable
Their drive isnt slowing down in career or in bed